Axon Enterprise, Inc. (NASDAQ:AXON) Shares Sold by Cim LLC

Cim LLC cut its holdings in Axon Enterprise, Inc. (NASDAQ:AXON) by 3.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,949 shares of the biotechnology company’s stock after selling 200 shares during the quarter. Cim LLC’s holdings in Axon Enterprise were worth $1,456,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. 9258 Wealth Management LLC acquired a new position in Axon Enterprise during the fourth quarter worth $204,000. Cambridge Investment Research Advisors Inc. boosted its holdings in shares of Axon Enterprise by 6.9% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 8,251 shares of the biotechnology company’s stock valued at $2,131,000 after purchasing an additional 535 shares during the last quarter. Advisory Services Network LLC acquired a new stake in Axon Enterprise during the fourth quarter worth about $180,000. TD Asset Management Inc raised its holdings in Axon Enterprise by 5.5% in the fourth quarter. TD Asset Management Inc now owns 23,575 shares of the biotechnology company’s stock valued at $6,090,000 after buying an additional 1,233 shares during the period. Finally, Focus Financial Network Inc. ADV purchased a new position in shares of Axon Enterprise in the 4th quarter valued at $258,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise Trading Down 0.1 %

NASDAQ:AXON opened at $399.22 on Wednesday. The stock has a market cap of $30.13 billion, a PE ratio of 116.73, a price-to-earnings-growth ratio of 10.59 and a beta of 0.94. Axon Enterprise, Inc. has a fifty-two week low of $190.01 and a fifty-two week high of $400.78. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52. The stock’s 50-day moving average is $359.52 and its two-hundred day moving average is $321.46.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The firm had revenue of $504.00 million for the quarter, compared to the consensus estimate of $478.35 million. During the same period in the previous year, the firm posted $0.80 earnings per share. The firm’s revenue was up 34.5% on a year-over-year basis. As a group, equities research analysts forecast that Axon Enterprise, Inc. will post 1.79 earnings per share for the current fiscal year.

Insider Transactions at Axon Enterprise

In related news, Director Jeri Williams sold 110 shares of Axon Enterprise stock in a transaction on Monday, September 30th. The stock was sold at an average price of $400.00, for a total transaction of $44,000.00. Following the completion of the sale, the director now owns 1,934 shares of the company’s stock, valued at $773,600. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Director Jeri Williams sold 110 shares of Axon Enterprise stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $400.00, for a total transaction of $44,000.00. Following the completion of the sale, the director now directly owns 1,934 shares in the company, valued at approximately $773,600. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Patrick W. Smith sold 80,300 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $371.78, for a total value of $29,853,934.00. Following the completion of the sale, the chief executive officer now directly owns 3,015,366 shares of the company’s stock, valued at approximately $1,121,052,771.48. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 318,091 shares of company stock valued at $115,706,734. 6.10% of the stock is owned by insiders.

Analyst Ratings Changes

AXON has been the subject of several analyst reports. Northland Securities upped their target price on shares of Axon Enterprise from $330.00 to $365.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th. Barclays increased their price target on Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Jefferies Financial Group initiated coverage on shares of Axon Enterprise in a research note on Wednesday, July 17th. They set a “buy” rating and a $385.00 target price for the company. Robert W. Baird lifted their price objective on shares of Axon Enterprise from $360.00 to $400.00 and gave the company an “outperform” rating in a research note on Tuesday, September 10th. Finally, Craig Hallum boosted their price objective on Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Axon Enterprise presently has a consensus rating of “Moderate Buy” and an average target price of $365.38.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.